Table 3.
Baseline characteristics.
| Psychiatric Meds; n (%) | Oxytocin (n=24) |
Placebo (n=24) |
Overall (n=48) |
|||
|---|---|---|---|---|---|---|
| Antidepressant | 8 (33.33%) | 11 (45.83%) | 19 (39.58%) | |||
| Anxiolytic | 4 (16.67%) | 3 (12.50%) | 7 (14.58%) | |||
| Antipsychotic | 6 (25.00%) | 4 (16.67%) | 10 (20.83%) | |||
| Mood stabilizer | 3 (12.50%) | 1 (4.17%) | 4 (8.33%) | |||
| None | 13 (54.17%) | 8 (33.33%) | 21 (43.75%) | |||
| Substance Use; Mean(SD) | 30-day* | Lifetime† | 30-day* | Lifetime† | 30-day* | Lifetime† |
| Methamphetamine | .38(.35) | .23(.16) | .43(.33) | .24(.16) | .40(.35) | .24(.16) |
| Primary IV; n (%) | 8 (33.33%) | 5 (20.83%) | 13 (27.08%) | |||
| Alcohol | .19(.29) | .25(.22) | .10(.15) | .21(.16) | .14(.24) | .23(.19) |
| Cannabis | .25(.42) | .14(.19) | .31(.42) | .20(.17) | .28(.43) | .17(.18) |
| Cocaine | .03(.10) | .10(.18) | .01(.02) | .10(.11) | .02(.07) | .10(.15) |
| Poppers (amyl nitrate) | .10(.22) | .04(.12) | .05(.10) | .01(.03) | .07(.17) | .03(.09) |
| Oxytocin (n=24) |
Placebo (n=23) |
Overall (n=47) |
||
|---|---|---|---|---|
| ACE; Mean(SD) | 5.33(2.67) | 5.65(2.14) | 5.49(2.46) | |
| Trait Anxiety‡; Mean(SD) | 48.26(13.93) | 52.56(10.14) | 50.41(12.51) | |
| Attachment Anxiety§; Mean(SD) | 27.87(7.43) | 27.09(8.12) | 27.48(7.88) | |
| RTCQ∣; Mean(SD) | Pre-Contemplation | −3.96(2.84) | −2.74(2.88) | −3.36(2.89) |
| Contemplation | 4.29(2.97) | 4.13(2.16) | 4.21(2.58) | |
| Action | 3.75(3.81) | 3.39(3.09) | 3.57(3.44) |
ACE=Adverse Childhood Experience Questionnaire, IV=intravenous, SD=standard deviation
*
Number of days used in past 30 days/30
†
Number of years used ≥3 times per week/age in years
‡
State-Trait Anxiety Inventory, trait items
§
Experiences in Close Relationships Scale – Short Form
∣
Readiness to Change Questionnaire